eV3 targets US PAD (peripheral artery disease) market:
This article was originally published in Clinica
Eyeing a wider market opportunity for its Protege EverFlex self-expanding stent, ev3 is to begin a US clinical trial to test the device as a treatment for peripheral artery disease (PAD). The product is already available in the US for the palliative treatment of malignant neoplasms in the biliary tree. The US trial, called DURABILITY II, will be the first study in the treatment of PAD to explore use of a single stent in the treatment of lesions as long as 16cm and will include rigorous, five-year follow-up on stent fracture, claimed the Plymouth, Minnesota firm. According to the American Heart Association, PAD affects 8 million people in the US.
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.